Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14389424 | 1.00 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL3451324 | 1.00 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL5953796 | 1.00 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL20633178 | 1.00 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL27370146 | 0.92 | ALB (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL24548327 | 0.88 | ALB (0.39) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL9803735 | 0.88 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL24548328 | 0.88 | ALB (0.39) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL2038395 | 0.87 | ABL1 (0.45) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL16552333 | 0.87 | ALB (0.39) | ABL1RIN1ALBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772208-B2 | 2′,3′-dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections | PHARMASSET, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080280846-A1 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS | PHARMASSET, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280846-A1 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS | DUT, DUS2, PNP | ABL1 3805/4885RIN1 2692/4885ALB 1305/4885 |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | NTPCR, PNP, TYMP | ABL1 134/4885RIN1 2288/4885ALB 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.